NUWE Nuwellis, Inc.

BEARISH Impact: 7/10 S-1
Horizon immediate Filed May 22, 2026 Processed 21d 15h ago SEC 0001140361-26-022629
IPO registration
Latest settled — T+5d
NUWE ▼ -35.16% at T+5d
SHORT call ✓ call won +35.16% · α vs SPY +36.38% · entry $0.9100 → $0.5900
Next anchor: T+20d in 10d
Currently $0.1400 · +84.62% from $0.9100 entry (call sign-flipped)
Entry anchored
May 22, 2026
via day open
T+1d
-16.48%
call +16.48% · α +16.50%
$0.7600
settled 18d ago
T+5d
-35.16%
call +35.16% · α +36.38%
$0.5900
settled 12d ago
T+20d
call — · α —
in 10d
T+60d
call — · α —
in 2mo

Executive Summary

Nuwellis, Inc. filed an S-1 registration statement for a best-efforts standby equity offering of up to 4,854,369 shares of common stock, pre-funded warrants, and warrants to raise approximately $5M at $1.03/share. The company has a $3M market cap, near-zero analyst bullishness, a history of operating losses (net loss of $17.5M in FY2025, accumulated deficit of $316.3M), and only enough cash to fund operations through Q2 2026. The offering is a dilutive emergency capital raise with no minimum and a termination date of June 30, 2026, and will further pressure the stock.

Actionable Insight

NUWE is racing to raise capital before its cash runs out (Q2 2026). The best-efforts structure with no minimum means the offering might close with far less than $4.4M. Massive dilution from the standalone offering plus the existing overhang of 4.8M warrants likely caps any rally. Watch for whether the warrants are priced with an exercise price far above market, making them near worthless to investors. The stock is a distressed micro-cap with delisting risk — short interest or avoidance warranted.

Key Facts

  • Up to 4,854,369 shares offered at assumed $1.03/share plus Series C/D warrants; no minimum offering requirement
  • Estimated net proceeds of ~$4.4M if fully sold; only $2.1M cash on hand as of March 31, 2026
  • Net loss of $17.5M in FY2025; accumulated deficit of $316.3M; going concern risk flagged by auditor (Baker Tilly)
  • Two material weaknesses in internal controls over financial reporting
  • Stock fell below $1.00 bid price in June 2025; only regained compliance via reverse split; Nasdaq proposed $5M market value listing rule could prompt delisting
  • Massive overhang: 4.8M warrants outstanding at weighted avg exercise price of $5.18 (far above current price of $1.03)
  • Warrants included in offering have placeholder exercise price; exercisability contingent on stockholder approval unless pricing conditions met
  • Ladenburg Thalmann acting as placement agent for 8% cash fee plus 3% warrant coverage

Financial Impact

Up to $5M gross raised; net ~$4.4M with only $2.1M cash on hand. Immediate dilution: 4.85M shares vs 2.64M outstanding (184% dilution). Offering has no minimum, so proceeds could be far lower.

dilutioncashgoing concern

Risk Factors

  • Best-efforts offering may fail to raise sufficient capital, forcing a restructuring or bankruptcy
  • Nasdaq delisting risk: proposed $5M market value rule and continued bid price risk after multiple reverse splits
  • Massive dilution: 4.85M new shares + 9.7M warrant shares + 4.8M existing warrants vs 2.64M shares outstanding
  • Going-concern opinion in auditor report; only $2.1M cash to fund operations
  • Two material weaknesses in internal controls; risk of further restatements or delays
  • Single-product dependency (Aquadex System) with limited market adoption and no direct competitors other than diuretics

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-1 Filing (Primary)0001140361-26-022629
Document: ny20073226x1_ex107.htm0001140361-26-022629
Document: ny20073226x1_ex5-1.htm0001140361-26-022629
Document: ny20073226x1_ex23-1.htm0001140361-26-022629
Document: 0001140361-26-022629-index-headers.html0001140361-26-022629
Document: 0001140361-26-022629-index.html0001140361-26-022629
Document: 0001140361-26-022629.txt0001140361-26-022629
14 reports for NUWE
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+5▲ +75.71%May 29, 2026
Filters
Rows
Reports for NUWE — sortable, filterable
Type Now
Jun 10, 2026
2d ago
8-K
BEARISH ★ 7/10
$0.1440 awaiting T+1awaiting T+1$0.1400 (+2.78%)
Jun 10, 2026
3d ago
Press Release
NEUTRAL ★ 4/10
$0.1440 awaiting T+1awaiting T+1$0.1400 (−2.78%)
Jun 9, 2026
4d ago
Press Release
BEARISH ★ 7/10
$0.1458 awaiting T+1awaiting T+1$0.1400 (+3.98%)
Jun 8, 2026
4d ago
424B4
BEARISH ★ 7/10
$0.1350 awaiting T+1awaiting T+1$0.1400 (−3.70%)
Jun 5, 2026
8d ago
Press Release
BEARISH ★ 8/10
$0.3007 awaiting T+1awaiting T+1$0.1400 (+53.44%)
Jun 4, 2026
8d ago
S-1/A
BEARISH ★ 7/10
$0.4300 $0.1700▲ +60.47%▲ +57.87%$0.1400 (+67.44%)
May 29, 2026
14d ago
S-1/A
BEARISH ★ 7/10
$0.7000 $0.5900▲ +15.71%▲ +15.86%$0.1400 (+80.00%)
May 22, 2026
21d ago
S-1
BEARISH ★ 7/10
$0.9100 $0.7600▲ +16.48%▲ +16.50%$0.1400 (+84.62%)
May 12, 2026
4w ago
Press Release
BEARISH ★ 7/10
$1.03 $1.03· 0.00%▲ +0.58%$0.1400 (+86.41%)
May 5, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$1.11 $1.09▼ −1.80%▼ −3.19%$0.1400 (−87.39%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (48h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access